Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance

BACKGROUND: Approximately 10% of non‐small cell lung cancers (NSCLCs) that harbor epidermal growth factor receptor (EGFR) gene mutations have in‐frame insertions in exon 20 of the EGFR gene. These tumors do not usually respond to currently available EGFR‐tyrosine kinase inhibitors (TKIs). Tarloxotin...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishino, Masaya, Suda, Kenichi, Koga, Takamasa, Ohara, Shuta, Fujino, Toshio, Soh, Junichi, Tirunagaru, Vijaya, Vellanki, Avanish, Doebele, Robert C., Mitsudomi, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107039/
https://www.ncbi.nlm.nih.gov/pubmed/33710795
http://dx.doi.org/10.1111/1759-7714.13931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107039/
https://www.ncbi.nlm.nih.gov/pubmed/33710795
http://dx.doi.org/10.1111/1759-7714.13931

Ejemplares similares